![]() Plasmid DNA is a key component in most gene therapy and gene-enabled cell therapy production processes. Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility. ![]() and GOSSELIES, BELGIUM – February 23, 2021 - Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |